✨ Medicines Consent and Renewal




9 SEPTEMBER NEW ZEALAND GAZETTE 2731

Schedule

Product: Amoxyclav.
Active Ingredient(s): Potassium clavulanate 149 mg equivalent to 125 mg clavulanic acid.
Amoxycillin (trihydrate) 294.1 mg equivalent to 250 mg amoxycillin.
Dosage Form: Film coated tablet.
NZ Sponsor: Alpha Pharmaceuticals Limited.
Manufacturer(s): Lek Pharmaceutical and Chemical Company, Ljubljana, Slovenia.

Product: Celebrex.
Active Ingredient(s): Celecoxib 100 mg.
Dosage Form: Capsule.
NZ Sponsor: Searle, Division of Monsanto New Zealand Limited.
Manufacturer(s): Searle & Co, San Juan, Puerto Rico.

Product: Celebrex.
Active Ingredient(s): Celecoxib 200 mg.
Dosage Form: Capsule.
NZ Sponsor: Searle, Division of Monsanto New Zealand Limited.
Manufacturer(s): Searle & Co, San Juan, Puerto Rico.

Product: Gastrolyte-R.
Active Ingredient(s): Potassium chloride 0.3 g.
Sodium citrate (dihydrate) 0.58 g.
Sodium chloride 0.35 g.
Rice powder 0.6 g.
Dosage Form: Powder.
NZ Sponsor: Rhone-Poulenc Rorer New Zealand Limited.
Manufacturer(s): Rhone-Poulenc Rorer Australia Pty Limited, Baulkham Hills, N.S.W., Australia.
Rhone-Poulenc Rorer Australia Pty Limited, West Footscray, Victoria, Australia.

Product: Paxam.
Active Ingredient(s): Clonazepam 0.5 mg.
Dosage Form: Tablet.
NZ Sponsor: Pacific Pharmaceuticals Limited.
Manufacturer(s): Alphapharm Pty Ltd, Brisbane, Queensland, Australia.

Product: Paxam.
Active Ingredient(s): Clonazepam 2 mg.
Dosage Form: Tablet.
NZ Sponsor: Pacific Pharmaceuticals Limited.
Manufacturer(s): Alphapharm Pty Ltd, Brisbane, Queensland, Australia.

Dated this 6th day of September 1999.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).

go9616

Renewal of Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Product: Actigall.
Active Ingredient(s): Ursodeoxycholic acid 150 mg.
Dosage Form: Capsule.
NZ Sponsor: Novartis New Zealand Limited.
Manufacturer(s): Novartis Pharma Stein AG/SA, Stein, Switzerland.
Novartis Pharmaceuticals Corporation, New York, U.S.A.

Note: This consent is valid for 2 years from the 7th day of September 1999.

Product: Actigall.
Active Ingredient(s): Ursodeoxycholic acid 300 mg.



Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1999, No 114


NZLII PDF NZ Gazette 1999, No 114





✨ LLM interpretation of page content

πŸ₯ Consent to the Distribution of a New Medicine (continued from previous page)

πŸ₯ Health & Social Welfare
6 September 1999
Medicines, Distribution, Consent, Amoxyclav, Celebrex, Gastrolyte-R, Paxam
  • G. R. Boyd, Chief Advisor, Safety and Regulation

πŸ₯ Renewal of Provisional Consent to the Distribution of a New Medicine

πŸ₯ Health & Social Welfare
7 September 1999
Medicines, Distribution, Renewal, Actigall